33 Participants Needed

Geriatric Assessment for Blood Disorders

Recruiting at 8 trial locations
RJ
Roni Tamari, MD profile photo
Overseen ByRoni Tamari, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, since the study includes a review of your current medications as part of the geriatric assessment, it's possible that adjustments might be recommended.

What data supports the effectiveness of the treatment Geriatric assessment (GA) pre-transplant for blood disorders?

Research shows that using geriatric assessment (GA) before transplants helps doctors better understand the overall health of older patients, which can lead to more personalized and effective treatment plans. This approach has been shown to improve the quality of care and outcomes for older adults with blood disorders by identifying health issues that might not be obvious and tailoring treatments to individual needs.12345

Is geriatric assessment generally safe for humans?

Geriatric assessment (GA) is generally considered safe for humans and is used to identify functional impairments in patients, which can help improve their care and outcomes, especially before treatments like stem cell transplants.26789

How does the geriatric assessment treatment differ from other treatments for blood disorders?

Geriatric assessment (GA) is unique because it evaluates the overall health and functional status of older patients before a transplant, allowing doctors to tailor treatments to individual needs. This approach helps identify hidden health issues, improve treatment outcomes, and reduce side effects, unlike standard treatments that may not consider these factors.1231011

What is the purpose of this trial?

This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with a myeloid malignancy including acute myeloid leukemia, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at patients' cognitive function (thinking processes), physical function, mobility (ability to move the body), mood, nutrition, and current medications to help decide the type of treatment they'll receive.Another purpose of this study is to see whether use of the geriatric assessment improves participants' quality of life. We will evaluate participants' quality of life through questionnaires.

Research Team

RJ

Richard j Lin, MD, PhD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for people aged 60 or older with certain blood disorders like acute myeloid leukemia and related conditions, who have a suitable donor for stem cell transplant. They must meet the standard criteria for transplantation and have less than 10% of immature cells (blasts) in their bone marrow.

Inclusion Criteria

have a matched related or unrelated donor, mismatched unrelated donor, or haploidentical donor
I have a confirmed diagnosis of a myeloid blood disorder.
have <10% blasts in bone marrow prior to transplant
See 2 more

Exclusion Criteria

This clinical trial does not involve cord blood donors.
My bone marrow has more than 10% cancer cells before transplant.
I have had a bone marrow or stem cell transplant.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Geriatric Assessment

Participants undergo a geriatric assessment to evaluate cognitive function, physical function, mobility, mood, nutrition, and current medications to determine treatment approach

1-2 weeks

Treatment

Participants receive risk-adapted conditioning regimens (MA or RIC/NMA) based on geriatric assessment, including chemotherapy and possibly radiation therapy

6-8 weeks

Follow-up

Participants are monitored for safety, effectiveness, and quality of life through questionnaires after treatment

1 year

Treatment Details

Interventions

  • Geriatric assessment (GA) pre-transplant
Trial Overview The study tests if a geriatric assessment before an allogeneic hematopoietic stem cell transplant can improve treatment outcomes and quality of life in older patients. This includes evaluating cognitive function, physical ability, mood, nutrition, and medications.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Geriatric participants with various blood disordersExperimental Treatment3 Interventions
1. Geriatric assessment (GA) pre-transplant 2. Risk-adapted allocation of conditioning intensity based on GA 3. GA-directed, longitudinal supportive care management

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+

References

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. [2022]
[Geriatric assessment of patients with hematological neoplasms]. [2018]
Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. [2021]
Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. [2020]
Biologic vs physiologic age in the transplant candidate. [2018]
Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years. [2023]
Serial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study. [2022]
The use of comprehensive geriatric assessment in older patients before allologeneic hematopoietic stem cell transplantation: A cross-sectional study. [2021]
Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns. [2019]
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. [2015]
[Risk Assessment of Hematologic Malignancy Treatment of the Elderly]. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security